• Rapport Therapeutics CEO Abraham Ceesay sold 51,499 common shares on Aug. 10-11.
• Sales prices ranged from USD 45.97 to USD 48.62 per share.
• Directly held stake fell to 486,108 shares.
• Indirect holdings totaled 102,458 shares through family trusts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-346995), on August 12, 2026, and is solely responsible for the information contained therein.